Effect of traumatic brain injury on mild behavioral impairment domains prior to all-cause dementia diagnosis and throughout disease progression.

Alzheimer's disease acquired brain injury apathy dementia geriatric psychiatry impulsivity mild behavioral impairment neurodegeneration neuropsychiatry social inappropriateness traumatic brain injury

Journal

Alzheimer's & dementia (New York, N. Y.)
ISSN: 2352-8737
Titre abrégé: Alzheimers Dement (N Y)
Pays: United States
ID NLM: 101650118

Informations de publication

Date de publication:
2022
Historique:
received: 23 11 2021
revised: 09 09 2022
accepted: 28 10 2022
entrez: 14 12 2022
pubmed: 15 12 2022
medline: 15 12 2022
Statut: epublish

Résumé

Traumatic brain injury (TBI) may alter dementia progression, although co-occurring neuropsychiatric symptoms (NPS) have received less attention. Originally designed to evaluate behavioral disruption prior to dementia diagnosis, the mild behavioral impairment (MBI) construct relates NPS to underlying neural circuit disruptions, with probable relevance across the progression of neurodegenerative disease. Therefore, the MBI construct may represent a valuable tool to identify and evaluate related NPS both preceding diagnosis of all-cause dementia throughout the progression of disease, representing an important area of inquiry regarding TBI and dementia. This investigation sought to evaluate the effect of TBI on NPS related by the MBI construct in participants progressing from normal cognitive status to all-cause dementia. Using National Alzheimer's Coordinating Center data, individuals progressing from normal cognition to all-cause dementia (clinician diagnosed) over 7.6 ± 3.0 years were studied to estimate prevalence of MBI domains in 124 participants with prior TBI history (57 with loss of consciousness [LOC] <5 minutes, 22 with LOC >5 min, 45 unknown severity) compared to 822 without. MBI domain prevalence was evaluated (1) prior to dementia onset (including only time points preceding time at dementia diagnosis, as per MBI's original definition) and (2) throughout dementia progression (evaluating all available time points, including both before and after dementia diagnosis). More severe TBI (LOC >5 minutes) was associated with the social inappropriateness MBI domain (adjusted odds ratio = 4.034; TBI history is associated with particular MBI profiles prior to onset and throughout progression of dementia. Understanding TBI's impact on inter-related NPS may help elucidate underlying neuropathology with implications for surveillance, detection, and treatment of behavioral concerns in aging TBI survivors. The mild behavioral impairment (MBI) construct links related neuropsychiatric symptoms (NPS) by probable underlying neural network dysfunction.Traumatic brain injury (TBI) with loss of consciousness (LOC) > 5 minutes was associated with pre-dementia social inappropriateness.TBI was associated with decreased motivation looking across dementia progression.TBI with LOC > 5 minutes was associated with abnormal perception/thought content.The MBI construct may be useful for examining related NPS across dementia progression.

Identifiants

pubmed: 36514440
doi: 10.1002/trc2.12364
pii: TRC212364
pmc: PMC9735270
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e12364

Informations de copyright

© 2022 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Déclaration de conflit d'intérêts

Dr. Cullum is the current Science Director of the Texas Alzheimer's Research & Care Consortium. Dr. Ismail has received fees for consultation and advisory work from Otsuka and Lundbeck. Dr. Lyketsos has received fees for consultation and advisory work from Astra‐Zeneca, Glaxo‐Smith Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office, Avanir, Zinfandel, BMS, Abvie, Janssen, Orion, Otsuka, Servier, Astellas, Roche, Karuna, SVB Leerink, Maplight, Axsome, and Global Institute on Addictions as well as grant support from the National Institute of Mental Health, National Institute on Aging, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, Glaxo‐Smith‐Kline, Eisai, Pfizer, Astra‐Zeneca, Lilly, Ortho‐McNeil, Bristol‐Myers, Novartis, National Football League, Elan, Functional Neuromodulation, and Bright Focus Foundation. The remaining authors declare no relevant conflicts of interest. Author disclosures are available in the supporting information.

Références

Nat Hum Behav. 2021 Dec;5(12):1707-1716
pubmed: 34239076
Nat Rev Neurol. 2018 Dec;14(12):711-722
pubmed: 30397256
Medicine (Baltimore). 2020 Aug 14;99(33):e21497
pubmed: 32871995
J Neurotrauma. 2019 Oct 1;36(19):2753-2761
pubmed: 31017049
J Alzheimers Dis. 2021;80(1):459-469
pubmed: 33554909
Aging Clin Exp Res. 2012 Aug;24(4):305-16
pubmed: 22102508
Neuroimage Clin. 2016 Dec 23;14:308-315
pubmed: 28210542
J Head Trauma Rehabil. 2018 Jan/Feb;33(1):E28-E35
pubmed: 28731870
Neuroscience. 2019 Apr 15;404:297-313
pubmed: 30711612
Chest. 2011 Jul;140(1):16-18
pubmed: 21729890
J Neuropsychol. 2018 Jun;12(2):176-199
pubmed: 27696753
J Neuropsychiatry Clin Neurosci. 2002 Fall;14(4):416-23
pubmed: 12426409
Front Neurol. 2021 Feb 23;12:617526
pubmed: 33708171
Front Hum Neurosci. 2014 Mar 31;8:67
pubmed: 24744712
Clin Neuropsychol. 2018 Apr;32(3):524-529
pubmed: 28988512
BMJ Open. 2021 Feb 11;11(2):e039767
pubmed: 33574141
Alzheimers Dement. 2021 Apr;17(4):686-691
pubmed: 33470043
Am J Geriatr Psychiatry. 2012 Feb;20(2):104-22
pubmed: 21841459
Brain. 2011 Sep;134(Pt 9):2502-12
pubmed: 21785117
EBioMedicine. 2018 Feb;28:21-30
pubmed: 29396300
Alzheimers Dement. 2016 Feb;12(2):195-202
pubmed: 26096665
Curr Psychiatry Rep. 2016 Nov;18(11):103
pubmed: 27726067
Neuroscience. 2015 Aug 6;300:94-103
pubmed: 25982564
Int Psychogeriatr. 2018 Feb;30(2):233-244
pubmed: 28879833
Front Neurosci. 2018 May 29;12:360
pubmed: 29896085
J Neuropsychiatry Clin Neurosci. 2010 Spring;22(2):166-72
pubmed: 20463110
J Cell Physiol. 2015 May;230(5):1024-32
pubmed: 25251017
Arch Neurol. 2008 Jul;65(7):963-7
pubmed: 18625866
NeuroRehabilitation. 2013;32(2):199-209
pubmed: 23535782
Acad Psychiatry. 2018 Oct;42(5):686-689
pubmed: 29022277
J Alzheimers Dis. 2020;74(2):699-711
pubmed: 32065793
Neuroimage. 2008 Feb 1;39(3):1014-26
pubmed: 17999940
J Alzheimers Dis. 2017;56(3):929-938
pubmed: 28059789
Int J Geriatr Psychiatry. 2021 Sep;36(9):1398-1406
pubmed: 33778998
Brain Commun. 2021 Mar 09;3(2):fcab026
pubmed: 33977261
J Alzheimers Dis. 2020;75(1):277-288
pubmed: 32250302
J Psychiatr Pract. 2004 May;10(3):196-9
pubmed: 15330228
Neuropsychologia. 2018 Sep;118(Pt B):54-67
pubmed: 28689673
Alzheimers Dement (Amst). 2019 Apr 18;11:333-339
pubmed: 31024987
J Neurotrauma. 2013 Jul 1;30(13):1117-22
pubmed: 23374007
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):210-6
pubmed: 17132964
Int Rev Psychiatry. 2020 Feb;32(1):61-70
pubmed: 31707905
Front Neurol. 2020 Feb 21;11:23
pubmed: 32153486
Nat Rev Neurosci. 2010 May;11(5):361-70
pubmed: 20216546
J Head Trauma Rehabil. 2022 May-Jun 01;37(3):E144-E156
pubmed: 34145157
Brain. 1995 Feb;118 ( Pt 1):279-306
pubmed: 7895011
Neurobiol Aging. 2012 Mar;33(3):620.e9-620.e22
pubmed: 21497950
Neuropharmacology. 2012 Mar;62(3):1342-8
pubmed: 21621548
J Neurotrauma. 2010 Nov;27(11):1983-95
pubmed: 20812776
Front Neurol. 2019 Feb 21;10:120
pubmed: 30846966
Front Behav Neurosci. 2017 Oct 26;11:195
pubmed: 29123473
Neuropsychology. 2018 May;32(4):410-416
pubmed: 29389151
Neurol Sci. 2020 May;41(5):1063-1074
pubmed: 31925612
J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9
pubmed: 11001602
PLoS Med. 2018 Jan 30;15(1):e1002496
pubmed: 29381704

Auteurs

Michael J C Bray (MJC)

Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA.

Barry R Bryant (BR)

Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA.

Aaron I Esagoff (AI)

Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA.

Lisa N Richey (LN)

Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA.

Carla Rodriguez (C)

Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA.

Akshay Krieg (A)

Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA.

Gardner McCullough (G)

Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA.

Jerry Tsai (J)

Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA.

William Tobolowsky (W)

Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA.

Sahar Jahed (S)

Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA.
Department of Psychiatry and Behavioral Medicine Medical College of Wisconsin Milwaukee Wisconsin USA.

C Munro Cullum (CM)

Department of Psychiatry University of Texas Southwestern Medical Center Dallas Texas USA.

Christian LoBue (C)

Department of Psychiatry University of Texas Southwestern Medical Center Dallas Texas USA.

Zahinoor Ismail (Z)

Department of Psychiatry, Cumming School of Medicine University of Calgary Calgary Alberta Canada.
Hotchkiss Brain Institute Cumming School of Medicine University of Calgary Calgary Alberta Canada.

Haijuan Yan (H)

Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA.

Constantine G Lyketsos (CG)

Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA.

Matthew E Peters (ME)

Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA.

Classifications MeSH